Market Overview

Geron Presents Updated Results from Imetelstat Phase 2 Proof-of-Concept Trial in Essential Thrombocythemia

Geron Corporation (NASDAQ: GERN) today announced that updated clinical results from the company's Phase 2 trial of imetelstat in essential thrombocytopenia (ET) were presented in an oral session at the 18th Congress of the European Hematology Association (EHA) in Stockholm by a principal investigator of the trial, Prof. Dr. med. Gabriela M. Baerlocher, of the University Hospital and University of Bern, Switzerland. ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The initial trial results from 14 patients with ET were presented at the American Society of Hematology (ASH) annual meeting in December 2012. The updated results, which showed robust hematologic and molecular responses in patients treated with imetelstat, included data for an additional six months of treatment and follow-up for the original 14 patients, as well as data from four additional patients enrolled in the

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Related Articles (GERN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters